/

Empresas

Al

No verificado

Alzheon, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

16 Comunicados de prensa

Ver todos los comunicados de prensa

14/04/2026

Eventos

Industria

Ciencia

Biotecnología

Farmacéutica

Salud

Psiquiatría

Medicina - Varios

Alzheon to Present Evidence of Neurovascular Protection from Trials with Oral Valiltramiprosate in APOE4/4 Alzheimer’s Patients Leading to Reduced Brain Edema and Microhemorrhage Risk at 2026 American Academy of Neurology Meeting in Chicago, Illinois

Fuente

Editor

1.00

0

07/04/2026

Industria

Ciencia

Biotecnología

Farmacéutica

Salud

Psiquiatría

Medicina - Varios

Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved Safety and Efficacy, and APOE4 Corrector Mechanism

Fuente

Editor

1.00

0

03/02/2026

Ciencia

Biotecnología

Farmacéutica

Salud

Medicina - Varios

Industria

Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients

Fuente

Editor

1.00

0

02/12/2025

Ciencia

Finanzas

Medicina - Varios

Asociaciones/Profesionales

Biotecnología

Sanidad

Farmacéutica

Salud

Industria

Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease

Fuente

Editor

1.00

0

19/11/2025

Eventos

Industria

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025

Fuente

Editor

1.00

0

14/10/2025

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Industria

Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease

Fuente

Editor

1.00

0

15/07/2025

Salud

Sanidad

Farmacéutica

Biotecnología

Web y redes sociales

Eventos

Industria

Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer’s Association International Conference in Toronto on July 30th, 2025

Fuente

Editor

1.00

0

10/04/2025

Eventos

Industria

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer’s Disease Carrying Two Copies of APOE4 Gene

Fuente

Editor

1.00

0

18/03/2025

Eventos

Industria

Ciencia

Biotecnología

Farmacéutica

Salud

Higiene alimentaria

Medicina - Varios

Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025

Fuente

Editor

1.00

0

25/02/2025

Ciencia

Biotecnología

Farmacéutica

Salud

Higiene alimentaria

Medicina - Varios

Eventos

Industria

Alzheon Announces Two New Scientific Papers Ahead of APOLLOE4 Phase 3 Trial Topline Symposium at ADPD Conference in Vienna on April 1st, Marking 15 Pathbreaking Peer-Reviewed Publications from Alzheon

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0